One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Open Accesshttps://doi.org/10.1182/blood-2018-99-119372
Copy DOI Journal: Blood |  Publication Date: Nov 29, 2018 |
 Citations: 1 |
Affiliation: Dana-Farber Cancer Institute, Mayo Clinic, Sidney Kimmel Comprehensive Cancer Center, Emory University, Indiana University, Rutgers, The State University of New Jersey, Stanford University, Medical College of Wisconsin, Fox Chase Cancer Center, Thomas Jefferson University, Hospital of the University of Pennsylvania, Vanderbilt University Medical Center, Northwestern University, Washington University in St. Louis, New York UniversityLongitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F)
Sign-in/Register to access full text options 
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
